News

Understanding the potential and limitations of new Acinetobacter baumannii active therapies.

The study found that vancomycin is more effective than metronidazole in achieving event-free survival for C difficile infections across all infection severity levels.

Transmission to humans is limited in the US, but concerns linger, especially in the wake of the COVID-19 pandemic.

The 2024-2025 season introduces a new vaccine formula with a monovalent component designed to enhance protection against current variants and reduce severe outcomes such as hospitalization and death.

In our latest roundtable series, we cover different aspects of HIV care. In this series, clinicians discuss diagnosis, therapies such as long-acting injectables, treating patients with multidrug resistance and more.

A focus group study reviewed provider practices to learn more about patient management and explore the potential to follow up with clinicians on important takeaways.

The NIH’s RECOVER Initiative has developed new symptom indices for Long COVID in school-age children and adolescents to find 14 symptoms overlapping between the two groups.

This study provides evidence that using DAAs reduces liver fibrosis and improves clinical outcomes.

In the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.

The study found that the vaccine, combined with presumptive antimalarial treatment, reduced Plasmodium falciparum parasitaemia and clinical malaria over two transmission seasons.

Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.

Mpox virus evades the innate immune system by interfering with antiviral pathways signaling and interferon responses, increasing replication, and complicating outbreak management, especially in non-endemic regions.

These skills are as critical as ever, and younger clinicians and learners need them to communicate and work professionally.

Recent study establishes that the generic glecaprevir/pibrentasvir is bioequivalent to the brand name version, offering the same therapeutic benefits.

Despite the differences in clinical presentation, MRSA strains remain susceptible to several key antibiotics, emphasizing the importance of targeted treatment and postoperative education in preventing MRSA infections.

We have complied some of our news stories and interviews from the last week to offer information on the differences between clade I and clade 2 mpox, why WHO declaring the global emergency is significant, looking at mpox in the United States, and more.

The Africa CDC's declaration of the mpox outbreak as a Public Health Emergency of Continental Security, GIGA-2339's upcoming phase 1 trials for HBV, ActivePure Medical's air decontamination system's success in reducing MRSA and HAIs, and more this week from Contagion.

NOWDiagnostics' represents a new option for early syphilis detection and aligns with ongoing efforts to improve STI screening.

The companies’ study met 1 of their 2 primary immunogenicity objectives.

The declaration was based on the outbreak's severity compared to past events and the differences between mpox Clade I and Clade II, which affect response strategies.

Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.

Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.

The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.

The Public Health Agency of Sweden reported the individual sought care at Region Stockholm and has been diagnosed with mpox caused by clade I.

The vaccine, Jynneos, manufactured by Bavarian Nordic, is being shipped to Africa to address the ongoing mpox outbreak.

Results reveal that the antiviral did not significantly improve lesion resolution in mpox patients compared to placebo, but it did report a lower mortality rate among participants than that seen in the broader DRC cases.

This is the very first such declaration by the Africa CDC since its inception in 2017.

Jeffery Silber MD, highlights VE303's consistent formulation as an advantage over traditional fecal transplants and discusses how the trial's patient-centric approach aims to improve outcomes and reduce healthcare-associated infections.